{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T03:32:53Z","timestamp":1771903973153,"version":"3.50.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2022CFC010"],"award-info":[{"award-number":["2022CFC010"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s11596-025-00061-z","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T13:55:36Z","timestamp":1749822936000},"page":"574-584","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rifaximin Inhibits Small Bowel Angiodysplasia-Associated Angiogenesis by Attenuating LncRNA-HIF1A-AS2\/miR-153-3p\/HIF-1 \u03b1\/Ang-2 Axis"],"prefix":"10.1007","volume":"45","author":[{"given":"Shuai","family":"Peng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An-ning","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"issue":"2","key":"61_CR1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.bpg.2007.10.026","volume":"22","author":"J Regula","year":"2008","unstructured":"Regula J, Wronska E, Pachlewski J. Vascular lesions of the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2008;22(2):313\u2013328.","journal-title":"Best Pract Res Clin Gastroenterol."},{"issue":"1","key":"61_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/apt.12527","volume":"39","author":"SS Sami","year":"2014","unstructured":"Sami SS, Al-Araji SA, Ragunath K. Review article: gastrointestinal angiodysplasia--pathogenesis, diagnosis and management. Aliment Pharmacol Ther. 2014;39(1):15\u201334","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"61_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.giec.2016.08.012","volume":"27","author":"CS Jackson","year":"2017","unstructured":"Jackson CS, Strong R. Gastrointestinal Angiodysplasia: Diagnosis and Management. Gastrointest Endosc Clin N Am. 2017;27(1):51\u201362.","journal-title":"Gastrointest Endosc Clin N Am."},{"issue":"1","key":"61_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.bpg.2016.11.004","volume":"31","author":"S Beg","year":"2017","unstructured":"Beg S, Ragunath K. Review on gastrointestinal angiodysplasia throughout the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2017;31(1):119\u2013125.","journal-title":"Best Pract Res Clin Gastroenterol."},{"issue":"4","key":"61_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1055\/s-0031-1291614","volume":"44","author":"S Lecleire","year":"2012","unstructured":"Lecleire S, Iwanicki-Caron I, Di-Fiore A, et al. Yield and impact of emergency capsule enteroscopy in severe obscure-overt gastrointestinal bleeding. Endoscopy. 2012;44(4):337\u2013342.","journal-title":"Endoscopy."},{"issue":"9","key":"61_CR6","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1038\/ajg.2015.246","volume":"110","author":"LB Gerson","year":"2015","unstructured":"Gerson LB,\u00a0Fidler JL,\u00a0Cave DR,\u00a0et al. ACG Clinical Guideline: Diagnosis and Management of Small Bowel Bleeding. Am J Gastroenterol.\u00a02015;110(9):1265\u20131287.","journal-title":"Am J Gastroenterol."},{"issue":"9","key":"61_CR7","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1080\/17474124.2018.1503532","volume":"12","author":"G Holleran","year":"2018","unstructured":"Holleran G, McNamara D. An overview of angiodysplasia: management and patient prospects. Expert Rev Gastroenterol Hepatol. 2018;12(9):863\u2013872.","journal-title":"Expert Rev Gastroenterol Hepatol."},{"issue":"1","key":"61_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/MEG.0000000000002027","volume":"34","author":"A Khan","year":"2021","unstructured":"Khan A, Gupta K, Chowdry M, et al. Thirty-day readmission rates, reasons, and costs for gastrointestinal angiodysplasia-related bleeding in the USA. Eur J Gastroenterol Hepatol.\u00a02021;34(1):11\u201317.","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"10","key":"61_CR9","first-page":"1021","volume":"34","author":"P Gkolfakis","year":"2022","unstructured":"Gkolfakis P, Fostier R, Tziatzios G, et al. Efficacy of pharmacologic treatment for treating gastrointestinal angiodysplasias-related bleeding: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2022;34(10):1021\u20131030.","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"10","key":"61_CR10","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1097\/MCG.0000000000000266","volume":"49","author":"J Romagnuolo","year":"2015","unstructured":"Romagnuolo J, Brock AS, Ranney N. Is Endoscopic Therapy Effective for Angioectasia in Obscure Gastrointestinal Bleeding?: A Systematic Review of the Literature. J Clin Gastroenterol. 2015;49(10):823\u2013830.","journal-title":"J Clin Gastroenterol."},{"issue":"2","key":"61_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/00004836-199209000-00004","volume":"15","author":"BS Lewis","year":"1992","unstructured":"Lewis BS, Salomon P, Rivera-MacMurray S, et\u00a0al. Does hormonal therapy have any benefit for bleeding angiodysplasia? J Clin Gastroenterol. 1992;15(2):99\u2013103.","journal-title":"J Clin Gastroenterol."},{"issue":"5","key":"61_CR12","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1053\/gast.2001.28650","volume":"121","author":"F Junquera","year":"2001","unstructured":"Junquera F, Feu F, Papo M, et\u00a0al. A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Gastroenterology. 2001;121(5):1073\u20131079.","journal-title":"Gastroenterology"},{"issue":"9318","key":"61_CR13","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S0140-6736(02)08542-2","volume":"359","author":"H Hodgson","year":"2002","unstructured":"Hodgson H. Hormonal therapy for gastrointestinal angiodysplasia. Lancet Lond Engl. 2002;359(9318):1630\u20131631.","journal-title":"Lancet Lond Engl."},{"issue":"3","key":"61_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1155\/2006\/859435","volume":"20","author":"A Szilagyi","year":"2006","unstructured":"Szilagyi A, Ghali MP. Pharmacological therapy of vascular malformations of the gastrointestinal tract. Can J Gastroenterol. 2006;20(3):171\u2013178.","journal-title":"Can J Gastroenterol."},{"issue":"7","key":"61_CR15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1080\/00365520310001969","volume":"38","author":"M Blich","year":"2003","unstructured":"Blich M, Fruchter O, Edelstein S, et al. Somatostatin therapy ameliorates chronic and refractory gastrointestinal bleeding caused by diffuse angiodysplasia in a patient on anticoagulation therapy. Scand J Gastroenterol. 2003;38(7):801\u2013803.","journal-title":"Scand J Gastroenterol."},{"issue":"3","key":"61_CR16","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1046\/j.1365-2141.2000.01897.x","volume":"108","author":"M Bowers","year":"2000","unstructured":"Bowers M, McNulty O, Mayne E. Octreotide in the treatment of gastrointestinal bleeding caused by angiodysplasia in two patients with von Willebrand's disease. Br J Haematol. 2000;108(3):524\u2013527.","journal-title":"Br J Haematol."},{"issue":"17","key":"61_CR17","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.medcli.2009.07.013","volume":"133","author":"IJ Molina","year":"2009","unstructured":"Infante MJ , Gallardo BP, Alonso MH. Octreotide long-acting release for severe obscure gastrointestinal haemorrhage in elderly patients with serious comorbidities. Med Clin (Spanish). 2009;133(17):667\u2013670.","journal-title":"Med Clin."},{"issue":"4","key":"61_CR18","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/S1590-8658(01)80087-6","volume":"33","author":"P Orsi","year":"2001","unstructured":"Orsi P, Guatti-Zuliani C, Okolicsanyi L. Long-acting octreotide is effective incontrolling rebleeding angiodysplasia of the gastrointestinal tract. Digest Liver Dis. 2001;33(4):330\u2013334.","journal-title":"Digest Liver Dis."},{"issue":"6","key":"61_CR19","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/apt.12000","volume":"36","author":"C Bon","year":"2012","unstructured":"Bon C, Aparicio T, Vincent M, et al. Long-acting somatostatin analogues decrease blood transfusionrequirements in patients with refractory gastrointestinal bleeding associated with angiodysplasia. Aliment Pharmacol Ther. 2012;36(6):587\u2013593.","journal-title":"Aliment Pharmacol Ther."},{"issue":"4","key":"61_CR20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.clinre.2016.02.003","volume":"40","author":"A Iannone","year":"2016","unstructured":"Iannone A, Principi M, Barone M, et al. Gastrointestinal bleeding from vascular malformations: Is octreotide effective to rescue difficult-to-treat patients? Clin Res Hepatol Gastroenterol. 2016;40(4):373\u2013377.","journal-title":"Clin Res Hepatol Gastroenterol."},{"issue":"2","key":"61_CR21","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ajg.2014.391","volume":"110","author":"R Marlu","year":"2015","unstructured":"Marlu R, Barthelon J, Durand A, et\u00a0al. Longterm therapy with bevacizumab in a patient with Glanzmann\u2019s thrombasthenia and recurrent digestive bleeding due to gastrointestinal angiodysplastic lesions. Am J Gastroenterol. 2015;110(2):352\u2013353.","journal-title":"Am J Gastroenterol."},{"issue":"4","key":"61_CR22","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1111\/hae.12977","volume":"22","author":"A Barr\u00e9","year":"2016","unstructured":"Barr\u00e9\u00a0A,\u00a0Dr\u00e9anic J,\u00a0Flaujac C, et\u00a0al. Is there a role for antiangiogenic therapy, bevacizumab, in the treatment of recurrent digestive bleeding due to angiodysplasia in Glanzmann\u2019s thrombasthenia? Haemophilia. 2016;22(4):e347\u2013e348.","journal-title":"Haemophilia."},{"issue":"9","key":"61_CR23","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","volume":"91","author":"RJ D'Amato","year":"1994","unstructured":"D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91(9):4082\u20134085.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"8","key":"61_CR24","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1016\/S0140-6736(04)16308-3","volume":"363","author":"ME Franks","year":"2004","unstructured":"Franks ME, Macpherson GR. Thalidomide FWD. Lancet. 2004;363(8):1802\u20131811.","journal-title":"Lancet."},{"issue":"2","key":"61_CR25","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/flgastro-2017-100870","volume":"9","author":"M McFarlane","year":"2018","unstructured":"McFarlane M, O'Flynn L, Ventre R, et al. Emerging role of thalidomide in the treatment of gastrointestinal bleeding. Frontline Gastroenterol. 2018;9(2):98\u2013104.","journal-title":"Frontline Gastroenterol."},{"issue":"1","key":"61_CR26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1572-0241.2003.07201.x","volume":"98","author":"M Shurafa","year":"2003","unstructured":"Shurafa M, Kamboj G. Thalidomide for the treatment of bleeding angiodysplasias. Am J Gastroenterol. 2003;98(1):221\u2013222.","journal-title":"Am J Gastroenterol."},{"issue":"10","key":"61_CR27","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1055\/s-2006-944829","volume":"38","author":"J Bauditz","year":"2006","unstructured":"Bauditz J, Lochs H, Voderholzer W. Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide. Endoscopy. 2006;38(10):1036\u20131039.","journal-title":"Endoscopy."},{"issue":"6","key":"61_CR28","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1007\/s10620-007-0067-z","volume":"53","author":"V Dabak","year":"2008","unstructured":"Dabak V, Kuriakose P, Kamboj G, et al. A pilot study of thalidomide in recurrent GI bleeding due to angiodysplasias. Dig Dis Sci. 2008;53(6):1632\u20131635.","journal-title":"Dig Dis Sci."},{"issue":"12","key":"61_CR29","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1097\/MEG.0b013e32832c9346","volume":"21","author":"P Kamalaporn","year":"2009","unstructured":"Kamalaporn P, Saravanan R, Cirocco M, et al. Thalidomide for the treatment of chronic gastrointestinal bleeding from angiodysplasias: a case series. Eur J Gastroenterol Hepatol. 2009;21(12):1347\u20131350.","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"2","key":"61_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4321\/S1130-01082012000200005","volume":"104","author":"A Garrido","year":"2012","unstructured":"Garrido A, Sayago M, L\u00f3pez J, et al. Thalidomide in refractory bleeding due to gastrointestinal angiodysplasias. Rev Esp Enferm Dig. 2012;104(2):69\u201371.","journal-title":"Rev Esp Enferm Dig."},{"issue":"33","key":"61_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004606","volume":"95","author":"H Chen","year":"2016","unstructured":"Chen H, Fu S, Feng N, et al. Bleeding recurrence in patients with gastrointestinal vascular malformation after thalidomide. Medicine (Baltimore). 2016;95(33):e4606","journal-title":"Medicine (Baltimore)."},{"issue":"5","key":"61_CR32","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1053\/j.gastro.2011.07.018","volume":"141","author":"ZZ Ge","year":"2011","unstructured":"Ge ZZ, Chen HM, Gao YJ, et\u00a0al. Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. Gastroenterology. 2011;141(5):1629\u20131637.e1\u2013e4.","journal-title":"Gastroenterology."},{"issue":"18","key":"61_CR33","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMoa2303706","volume":"389","author":"H Chen","year":"2023","unstructured":"Chen H, Wu S, Tang M, et al. Thalidomide for recurrent bleeding due to small-intestinal angiodysplasia. N Engl J Med. 2023;389(18):1649\u20131659.","journal-title":"N Engl J Med."},{"issue":"12","key":"61_CR34","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1007\/s10620-014-3257-5","volume":"59","author":"Y Li","year":"2014","unstructured":"Li Y, Fu S, Chen H, et al. Inhibition of endothelial Slit2\/Robo1 signaling by thalidomide restrains angiogenesis by blocking the PI3K\/Akt pathway. Dig Dis Sci. 2014;59(12):2958\u20132966.","journal-title":"Dig Dis Sci."},{"issue":"4","key":"61_CR35","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1111\/j.1572-0241.1999.01017.x","volume":"94","author":"F Junquera","year":"1999","unstructured":"Junquera F, Saperas E, de Torres I, et al. Increased expression of angiogenic factors in human colonic angiodysplasia. Am J Gastroenterol. 1999;94(4):1070\u20131076.","journal-title":"Am J Gastroenterol."},{"issue":"3","key":"61_CR36","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1046\/j.1365-2796.2000.00717-2.x","volume":"248","author":"H Fujita","year":"2000","unstructured":"Fujita H, Momoi M, Chuganji Y, et al. Increased plasma vascular endothelial growth factor levels in patients with angiodysplasia. J Intern Med. 2000;248(3):268\u2013269.","journal-title":"J Intern Med."},{"issue":"10","key":"61_CR37","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/MCG.0000000000000260","volume":"49","author":"G Holleran","year":"2015","unstructured":"Holleran G, Hall B, O'Regan M, et al. Expression of Angiogenic Factors in Patients with Sporadic Small Bowel Angiodysplasia. J Clin Gastroenterol. 2015;49(10):831\u2013836.","journal-title":"J Clin Gastroenterol."},{"issue":"6","key":"61_CR38","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/j.1440-1746.2011.06967.x","volume":"27","author":"H Tan","year":"2012","unstructured":"Tan H, Chen H, Xu C, et al. Role of vascular endothelial growth factor in angiodysplasia: an interventional study with thalidomide. J Gastroenterol Hepatol. 2012;27(6):1094\u20131101.","journal-title":"J Gastroenterol Hepatol."},{"issue":"5","key":"61_CR39","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1751-2980.2011.00506.x","volume":"12","author":"HH Tan","year":"2011","unstructured":"Tan HH, Ge ZZ, Gao YJ, et al. The role of HIF-1, angiopoietin-2, Dll4 and Notch1 in bleeding gastrointestinal vascular malformations and thalidomide-associated actions: a pilot in vivo study. J Dig Dis. 2011;12(5):349\u2013356.","journal-title":"J Dig Dis."},{"issue":"2","key":"61_CR40","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/1751-2980.12114","volume":"15","author":"Q Feng","year":"2014","unstructured":"Feng Q, Tan HH, Ge ZZ, et al. Thalidomide-induced angiopoietin 2, Notch1 and Dll4 downregulation under hypoxic condition in tissues with gastrointestinal vascular malformation and human umbilical vein endothelial cells. J Dig Dis. 2014;15(2):85\u201395.","journal-title":"J Dig Dis."},{"issue":"6","key":"61_CR41","doi-asserted-by":"publisher","first-page":"27280","DOI":"10.1038\/srep27280","volume":"1","author":"N Feng","year":"2016","unstructured":"Feng N, Chen H, Fu S. HIF-1\u03b1 and HIF-2\u03b1 induced angiogenesis in gastrointestinal vascular malformation and reversed by thalidomide. Sci Rep. 2016;1(6):27280.","journal-title":"Sci Rep."},{"issue":"1","key":"61_CR42","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.biopha.2017.09.113","volume":"96","author":"L Li","year":"2017","unstructured":"Li L, Wang M, Mei Z, et al. lncRNAs HIF1A-AS2 facilitates the up-regulation of HIF-1alpha by sponging to miR-153-3p, whereby promoting angiogenesis in HUVECs in hypoxia. Biomed Pharmacother. 2017;96(1):165\u2013172.","journal-title":"Biomed Pharmacother."},{"issue":"24","key":"61_CR43","doi-asserted-by":"publisher","first-page":"5207","DOI":"10.1007\/s00018-020-03465-3","volume":"77","author":"CT Tang","year":"2020","unstructured":"Tang CT, Zhang QW, Wu S, et al. Thalidomide targets EGFL6 to inhibit EGFL6\/PAX6 axis-driven angiogenesis in small bowel vascular malformation. Cell Mol Life Sci.\u00a02020;77(24):5207\u20135221.","journal-title":"Cell Mol Life Sci."},{"issue":"2","key":"61_CR44","first-page":"51","volume":"14","author":"JJ Descombe","year":"1994","unstructured":"Descombe JJ, Dubourg D, Picard M, et al. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res. 1994;14(2):51\u201356.","journal-title":"Int J Clin Pharmacol Res."},{"issue":"1","key":"61_CR45","first-page":"19","volume":"5","author":"DE Baker","year":"2005","unstructured":"Baker DE. Rifaximin: a nonabsorbed oral antibiotic. Rev Gastroenterol Disord. 2005;5(1):19\u201330.","journal-title":"Rev Gastroenterol Disord."},{"issue":"29","key":"61_CR46","doi-asserted-by":"publisher","first-page":"6638","DOI":"10.3748\/wjg.v22.i29.6638","volume":"22","author":"RH Shayto","year":"2016","unstructured":"Shayto RH, Abou Mrad R, Sharara AI. Use of rifaximin in gastrointestinal and liver diseases. World J Gastroenterol. 2016;22(29):6638\u20136651.","journal-title":"World J Gastroenterol."},{"issue":"1","key":"61_CR47","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/apt.13436","volume":"43","author":"RB Sartor","year":"2016","unstructured":"Sartor RB. Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;43(1):27\u201336.","journal-title":"Aliment Pharmacol Ther."},{"issue":"10","key":"61_CR48","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/apt.12735","volume":"39","author":"P Schoenfeld","year":"2014","unstructured":"Schoenfeld P, Pimentel M, Chang L, et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2014;39(10):1161\u20131168.","journal-title":"Aliment Pharmacol Ther."},{"issue":"12","key":"61_CR49","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2165\/00003495-200565120-00011","volume":"65","author":"GW Robins","year":"2005","unstructured":"Robins GW, Wellington K. Rifaximin: a review of its use in the management of traveller\u2019s diarrhoea. Drugs. 2005;65(12):1697\u20131713.","journal-title":"Drugs."},{"issue":"1","key":"61_CR50","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/apt.12111","volume":"37","author":"E Mattila","year":"2013","unstructured":"Mattila E, Arkkila P, Mattila PS, et al. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2013;37(1):122\u2013128.","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"61_CR51","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/apt.13437","volume":"43","author":"M Pimentel","year":"2016","unstructured":"Pimentel M. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2016;43(1):37\u201349.","journal-title":"Aliment Pharmacol Ther."},{"issue":"11","key":"61_CR52","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1097\/MEG.0000000000000967","volume":"29","author":"ES Ibrahim","year":"2017","unstructured":"Ibrahim ES, Alsebaey A, Zaghla H, et al. Long-term rifaximin therapy as a primary prevention of hepatorenal syndrome. Eur J Gastroenterol Hepatol. 2017;29(11):1247\u20131250.","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"5","key":"61_CR53","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/apt.13928","volume":"45","author":"L Gatta","year":"2017","unstructured":"Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther. 2017;45(5):604\u2013616.","journal-title":"Aliment Pharmacol Ther."},{"issue":"6","key":"61_CR54","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.dld.2017.01.164","volume":"49","author":"R Cuomo","year":"2017","unstructured":"Cuomo R, Barbara G, Annibale B. Rifaximin and diverticular disease: Position paper of the Italian Society of Gastroenterology (SIGE). Dig Liver Dis. 2017;49(6):595\u2013603.","journal-title":"Dig Liver Dis."},{"issue":"1","key":"61_CR55","first-page":"25","volume":"88","author":"G Maconi","year":"2017","unstructured":"Maconi G. Diagnosis of symptomatic uncomplicated diverticular disease and the role of Rifaximin in management. Acta Biomed. 2017;88(1):25\u201332.","journal-title":"Acta Biomed."},{"issue":"5","key":"61_CR56","first-page":"1151","volume":"21","author":"M Mariani","year":"2017","unstructured":"Mariani M, Zuccaro V, Patruno SF, et al. The impact of rifaximin in the prevention of bacterial infections in cirrhosis. Eur Rev Med Pharmacol Sci. 2017;21(5):1151\u20131158.","journal-title":"Eur Rev Med Pharmacol Sci."},{"issue":"3","key":"61_CR57","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/MEG.0000000000000786","volume":"29","author":"M Bruyneel","year":"2017","unstructured":"Bruyneel M, Serst\u00e9 T,\u00a0Libert W, et al. Improvement of sleep architecture parameters in cirrhotic patients with recurrent hepatic encephalopathy with the use of rifaximin. Eur J Gastroenterol Hepatol. 2017;29(3):302\u2013308.","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"2","key":"61_CR58","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3892\/ijo.2016.3550","volume":"49","author":"G Esposito","year":"2016","unstructured":"Esposito G, Gigli S, Seguella L, et al. Rifaximin, a non-absorbable antibiotic, inhibits the release of pro-angiogenic mediators in colon cancer cells through a pregnane X receptor-dependent pathway. Int J Oncol. 2016;49(2):639\u2013645.","journal-title":"Int J Oncol."},{"issue":"4","key":"61_CR59","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jhep.2011.11.013","volume":"56","author":"Q Zhu","year":"2012","unstructured":"Zhu Q, Zou L, Jagavelu K, et al. Intestinal decontamination inhibits TLR4 dependent fibronectin mediated crosstalk between stellate cells and endothelial cells in liver fibrosis in mice. J Hepatol. 2012;56(4):893\u2013889.","journal-title":"J Hepatol."},{"issue":"4","key":"61_CR60","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1097\/MPG.0b013e3181a0d269","volume":"49","author":"P Muniyappa","year":"2009","unstructured":"Muniyappa P, Gulati R, Mohr F, et al. Use and safety of rifaximin in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009;49(4):400\u2013404.","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"11","key":"61_CR61","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/apt.13181","volume":"41","author":"C Yang","year":"2015","unstructured":"Yang C, Singh P, Singh H, et al. Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41(11):1079\u20131093.","journal-title":"Aliment Pharmacol Ther."},{"issue":"11","key":"61_CR62","first-page":"5767","volume":"35","author":"GV Sherbet","year":"2015","unstructured":"Sherbet GV. Therapeutic Potential of Thalidomide and Its Analogues in the Treatment of Cancer. Anticancer Res. 2015;35(11):5767\u20135772.","journal-title":"Anticancer Res."},{"issue":"4","key":"61_CR63","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3892\/ijmm.2016.2724","volume":"38","author":"X Wang","year":"2016","unstructured":"Wang X, Shen Y, Li S, et al. Importance of the interaction between immune cells and tumor vasculature mediated by thalidomide in cancer treatment (Review). Int J Mol Med. 2016;38(4):1021\u20131029.","journal-title":"Int J Mol Med."},{"issue":"5","key":"61_CR64","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","volume":"77","author":"SA Holstein","year":"2017","unstructured":"Holstein SA, McCarthy PL. Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience. Drugs. 2017;77(5):505\u2013520.","journal-title":"Drugs."},{"issue":"3","key":"61_CR65","first-page":"3313","volume":"15","author":"X Zhang","year":"2018","unstructured":"Zhang X, Luo H. Effects of thalidomide on growth and VEGF-A expression in SW480 colon cancer cells. Oncol Lett. 2018;15(3):3313\u20133320.","journal-title":"Oncol Lett."},{"issue":"1","key":"61_CR66","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12072-020-10117-y","volume":"15","author":"X Zeng","year":"2021","unstructured":"Zeng X, Sheng X, Wang PQ, et al. Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis. Hepatol Int. 2021;15(1):155\u2013165.","journal-title":"Hepatol Int."}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-025-00061-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-025-00061-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-025-00061-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T08:03:41Z","timestamp":1751875421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-025-00061-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["61"],"URL":"https:\/\/doi.org\/10.1007\/s11596-025-00061-z","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"value":"2096-5230","type":"print"},{"value":"2523-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"28 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study was approved by the Ethics Committee of Renmin Hospital of Wuhan University (Approval No. WDRY2024-K162), and all patients provided informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}